Tesaro Inc., of Waltham, Mass., reported $53.9 million in second-quarter sales of its PARP inhibitor, Zejula (niraparib), and $2.6 million in sales of Varubi/Varuby (rolapitant) for chemotherapy-induced nausea and vomiting. The company reported a net loss of $166.7 million, or $3.04 per share, and ended the quarter with $575.1 million in cash and cash equivalents. Shares of Tesaro (NASDAQ:TSRO) fell $8.31, or 23.6 percent, to close Friday at $26.97.